Beta-Agonists, Inhaled Long Acting

• Inhalers for Asthma and COPD - Jun 06, 2024
• Inhalers for Asthma and COPD - Feb 01, 2024
• Inhalers for Asthma/COPD - Dec 01, 2022
• Asthma and COPD maintenance medications - Oct 01, 2020
• Asthma and COPD Maintenance Medications - May 23, 2019
• Class Scan: Asthma and COPD - Jan 25, 2018
• Drugs to Treat Asthma and Chronic Obstructive Pulmonary Disease (COPD) - Sep 29, 2016
• Asthma and COPD - Sep 24, 2015
• COPD/Asthma Class Update - Jul 31, 2014
• COPD Class Update and Breo Ellipta New Drug Evaluation - Nov 21, 2013
• Class Scan: COPD Medications - Sep 26, 2013
• Drug Class Review: Controller Medications for Asthma - Jul 25, 2013
• Class Update: Asthma Controllers - May 31, 2012
• Abbreviated Class Review: COPD - Feb 23, 2012

• August 2023 - 2023 Global Initiative for Chronic Obstructive Lung Disease Report: Focus on Revised Recommendations for Inhaler Products
• May 2017 - Updates in the Management of Chronic Obstructive Pulmonary Disease
• June 2013 - Updates and Future Perspectives in the Management of Stable Chronic Obstructive Pulmonary Disease

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.